| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/07/2005 | US20050148662 compounds possess the ability to recognize and promote oxidation and allow for scission of a nucleic acid at specific positions and splitting (if exposed to piperidine) |
| 07/07/2005 | US20050148661 calcium is in gluconate, chloride, bromogalactogluconate, gluconolactate or carbonate form, and the magnesium is in sulfate or pidolate form |
| 07/07/2005 | US20050148660 Novel retinol derivative and cosmetic composition comprising the same |
| 07/07/2005 | US20050148658 theaflavin and a carrier; theaflavin-3,3'-digal (TF-3), theaflavin-3-monogallate (TF-2), theaflavin-3 gallate, theaflavin-3'-gallate, and/or thearubigin |
| 07/07/2005 | US20050148657 9, 10-Alpha, alpha-OH-taxane analogs and methods for production thereof |
| 07/07/2005 | US20050148656 Carboxylic derivates |
| 07/07/2005 | US20050148654 Statin-carboxyalkylether combinations |
| 07/07/2005 | US20050148653 Polymaleimide compounds and their medical use |
| 07/07/2005 | US20050148651 Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl-(amine- derived)] compounds and analogues thereof, and to products obtained therefrom |
| 07/07/2005 | US20050148649 Substituted arylpyrazoles |
| 07/07/2005 | US20050148648 Cystic fibrosis transmembrane conductance regulator; ABC transporter mediated diseases like cystic fibrosis; 5-methoxy-N-((1-(3,4-dimethoxyphenyl)-cyclohexyl)methyl)benzofuran-2-carboxamide; or sulfonamide analogs; chloride or bicarbonate channel modulators |
| 07/07/2005 | US20050148647 comprising amino acids in amounts approximately proportional to that of amino acids obtained from the hydrolysis of casein |
| 07/07/2005 | US20050148646 Dicationic triaryl analogs as anti-protozoan agents |
| 07/07/2005 | US20050148645 Improved solubility in organic solvents, facilitating the separation, purification and identification of the components; antimalarial, an antiproliferative agent, an antifungal agent, an antibacterial, or an anti-inflammatory agent |
| 07/07/2005 | US20050148644 Ligands for Inosine-5'-monophosphate dehydrogenase; antiviral, antiinflammatory, antibiotics, transplant rejection, autoimmune disease, , antipsoriatic immunosuppressants; 3-uriedo benzyl carbamate derivatives; high potency, side effects reduction; bioavailability; antivascular hyperproliferative |
| 07/07/2005 | US20050148643 Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme |
| 07/07/2005 | US20050148642 Metabotropic glutamate receptor antagonists containing a saturated oxygen- or nitrogen-containing ring or a cycloalkyl ring, e.g., N-methyl-N-neopentyl-6-[(oxetan-3-ylamino)methyl]thiazolo[3,2-a]benzimidazole-2-carboxamide, having excellent oral activity, used especially for treating neuropathic pain |
| 07/07/2005 | US20050148641 2-Methylthiazolidine-2,4-dicarboxylic acid and salts thereof for the treatment of neurodegenerative diseases |
| 07/07/2005 | US20050148638 Increasing contractile force in cardiac muscle fiber by administering a N-[(3-yloxy)-phenyl]-arylamide derivatives; modulating at the cardiac sarcomere (cardiac beta myosin) for congestive heart failure |
| 07/07/2005 | US20050148637 Neurotrophic low molecular weight ketones and tioester compounds for treatment of nervous system disorders and neurodegenerative conditions |
| 07/07/2005 | US20050148636 Useful aroyl pyrrole heteroaryl methanones and methanols |
| 07/07/2005 | US20050148633 Method for modulating calcium ion-release-activated calcium ion channels |
| 07/07/2005 | US20050148632 Therapeutic agent for intestinal diseases and visceral pain |
| 07/07/2005 | US20050148631 Modulation of steroid enzymes in mammals as antidiabetic agents, for treatment of obesity, vision defects, lowering fats in blood, for treatment of osteoporosis, tuberculosis or atherosclerosis in mammals |
| 07/07/2005 | US20050148630 Gastrointestinal disorders such as chronic constipation or other disorders |
| 07/07/2005 | US20050148629 Hydroxyamidealkylsulfonamide compounds for anthrax treatment |
| 07/07/2005 | US20050148628 Treatment of malaria with mixtures of artesunate and mefloquine for three days and blister packs of medicine |
| 07/07/2005 | US20050148627 Benzopyran compounds for use in the treatment and prevention of inflammation related conditions |
| 07/07/2005 | US20050148626 Novel thromodulin expression promoters |
| 07/07/2005 | US20050148625 Use of estrogen antagonists and estrogen agonists inhibiting pathological conditions |
| 07/07/2005 | US20050148624 Enzyme inhibitors with isoquinolinone structures |
| 07/07/2005 | US20050148623 HIV protease inhibiting compounds |
| 07/07/2005 | US20050148622 Process for preparing acid salts of gemifloxacin |
| 07/07/2005 | US20050148619 Sulfonamido ether substituted imidazoquinolines |
| 07/07/2005 | US20050148618 Tricyclic n-acyl compounds |
| 07/07/2005 | US20050148616 Inhibitor of TNF-alpha and IL-1beta production |
| 07/07/2005 | US20050148615 Analgesics, neuropathic pain, reflex sympathetic dystrophy, spasticity, or bipolar disorder; can be use in combination with morphine |
| 07/07/2005 | US20050148614 Combination of active ingredients for the treatment of senile dementia of the Alzheimer type |
| 07/07/2005 | US20050148613 Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
| 07/07/2005 | US20050148612 Reversing, postponing or preventing the occurrence of GTN tolerance and/or generation of reactive oxygen species from mitochondria |
| 07/07/2005 | US20050148611 Compounds capable of activating cholinergic receptors |
| 07/07/2005 | US20050148609 Tetrazole substituted quinazoline compounds for antiproliferation agents |
| 07/07/2005 | US20050148608 Chymase enzyme inhibitors for drugs in vascular systems using sulfonylurea derivatives |
| 07/07/2005 | US20050148607 Administering to show overactivation or expression from diagnosis of diseases, immunoassay, anticancer agents or skin disorders |
| 07/07/2005 | US20050148605 Modulation of protein tyrosine kinases for treatment of diseases with prodrugs |
| 07/07/2005 | US20050148603 Compositions useful as inhibitors of protein kinases |
| 07/07/2005 | US20050148601 Neurokinin-3 receptor modulators: diaryl imidazole derivatives |
| 07/07/2005 | US20050148600 Inhibition of lysophatidic acetyltranferase beta as enzyme inhibitors to control obesity |
| 07/07/2005 | US20050148597 Controlled release of sterile freeze dried aripirazole in water for intramuscular injection |
| 07/07/2005 | US20050148594 Salt with choline, ethanolamine, diethanolamine, piperazine, calcium or tromethamine, optionally embedded in an enteric binder; recrystallization prevention; improved bioavailability and photostability |
| 07/07/2005 | US20050148593 Compounds, compositions, and methods |
| 07/07/2005 | US20050148591 Tartrate salts of 5,8,14-triazatetracyclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen and pharmaceutical compositions thereof |
| 07/07/2005 | US20050148590 4-[3-Hydroxyimino-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-propenyl]-benzoic acid; emphysema; respiratory system and skin disorder; acne and psoriasis; side effect reduction; improved pharmacology |
| 07/07/2005 | US20050148589 Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders |
| 07/07/2005 | US20050148588 LFA-1 antagonist compounds |
| 07/07/2005 | US20050148587 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders |
| 07/07/2005 | US20050148586 Quinoxalinones |
| 07/07/2005 | US20050148585 Treating chronic venous ulcers, arterial ulcers, chronic decubitus, acute wounds with a cGMP PDE5 inhibitor; improved blood supply to the wound region; sildenafil analog; 5-[2-ethoxy-5-(4-ethylpiperazin-1ylsulfonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3 d]pyrimidin-7-one |
| 07/07/2005 | US20050148584 N-(3-(2-(4-morpholino)ethyloxy)phenyl)-N-{(cis3-(benzylamino)cyclohexyl)methyl}-N'-phenylurea; useful for the treatment of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel syndrome |
| 07/07/2005 | US20050148583 1-[2-[2-(4-Diethylcarbamoylbenzyl)phenoxy]ethyl]-4-(1,3-dihydro-2H-benzimidazol-2-on-1-yl)piperidine; agonist, antagonist, partial or inverse agonist; schizophrenia, depression, cerebral apoplexy, epilepsy, Alzheimer's disease, and Parkinson's disease; analgesic; pharmacokinetics |
| 07/07/2005 | US20050148582 N-[1-butyl-4-piperidinylmethyl[3,4-dihydro-2 oxazino[3,2-a indole-10 carboxamide as drugs with Cahpo4 or Ca3/po4/2 fillers or binders for use in treatment of irritable bowel syndrome, urinry incontience or arrhythmias |
| 07/07/2005 | US20050148581 Quinolines; 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-ol; Mycobacterium tuberculosis, M. bovis, M. avium and M. marinum; reduces the total length of treatment and the frequency of drug administration; multi-drug and antibiotic resistance |
| 07/07/2005 | US20050148580 Non-opioid analgesics for chronic and acute pain; 1-[1-(p-phenylbenzyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione; modulation of the opioid and ORL I receptors; agonist or antagonist activity at the CNS mu, delta and kappa receptors greater than morphine |
| 07/07/2005 | US20050148578 1H-8-oxa-1-aza-dibenzo[e,h]azulene; dual inhibitors of tumour necrosis factor(alpha) and interleukin 1; antiinflammatory, analgesics |
| 07/07/2005 | US20050148577 2-methyl-1,8-dioxa-dibenzo[e,h]azulene; potentiation; dual inhibitors of tumour necrosis factor(alpha) and interleukin 1; antiinflammatory, analgesics |
| 07/07/2005 | US20050148576 Dibenzo[b.f]oxazolo-azulines, -oxepines and -thiepines; antiinflammatories; analgesics |
| 07/07/2005 | US20050148575 (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury |
| 07/07/2005 | US20050148574 Imidazole compositions useful as inhibitors of protein kinases |
| 07/07/2005 | US20050148573 Benzimidazolone compounds having 5-HT4 receptor agonistic activity |
| 07/07/2005 | US20050148572 2-(2,4-difluorophenyl)-2-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-isobutyl-2,5-dioxopiperazin-1-yl]-N,N-dimethylethanamide; to suppress uterine contractions; cyclization of leucine analogs |
| 07/07/2005 | US20050148571 Method of treating bacterial infections using gemifloxacin or a salt thereof and a betha-Lactam antibiotic |
| 07/07/2005 | US20050148570 Antimicrobial hydroxy-substituted fluorene or (cyclo)alkylidenediphenol derivatives e.g. 2,2-Bis(4-hydroxy-3-methylphenyl)heptane or penem or cephalosporin derivatives thereof; antiseptics |
| 07/07/2005 | US20050148569 Targeted oxidative therapeutic formulation |
| 07/07/2005 | US20050148568 Treating sarcocystis protozoa infected horses; peroxidic species from oxidation of such as geraniol, penetrating solvent;, metal chelated dye and aromatic redox compound; activating with ionizing radiation |
| 07/07/2005 | US20050148565 17 beta )-3-[2-dimethylamino]-ethoxy]- Delta 1,3,5(10)-estrien-17-ol; selective estrogen receptor modulators (SERMs) upon MCF-7 cells with antiestrogenic activity and minimal side effects; endometrial cancer |
| 07/07/2005 | US20050148563 Pulmonary disease treatment |
| 07/07/2005 | US20050148562 Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| 07/07/2005 | US20050148561 Novel triterpene derivatives, preparation thereof and use thereof |
| 07/07/2005 | US20050148560 Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol |
| 07/07/2005 | US20050148559 Fewer side effects; usable for longer period of time; lower recurrence rates after discontinuation; combination of progestogen and androgen components; kits |
| 07/07/2005 | US20050148558 Stabilized hydroxyvitamin D |
| 07/07/2005 | US20050148557 Use of Vitamin Ds to treat kidney disease |
| 07/07/2005 | US20050148556 Compositions and methods for increasing HDL and HDL-2b levels |
| 07/07/2005 | US20050148555 Synergistic use of p38 MAP kinase inhibitor and second active ingredient; inhibiting cytokine production; chronic obstructive pulmonary disease (COPD) |
| 07/07/2005 | US20050148553 Use of tigecycline, alone, or in combination with rifampin to treat osteomyelitis and/or septic arthritis |
| 07/07/2005 | US20050148552 Administering low concentration tetracycline compound; below antibacterial activity level |
| 07/07/2005 | US20050148550 Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine compounds |
| 07/07/2005 | US20050148549 Compositions and methods for inhibition of phospholipase a2 mediated inflammation |
| 07/07/2005 | US20050148548 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors |
| 07/07/2005 | US20050148546 Solid phase acid hydrolysis on cation exchange resin; high yield, stability and purity with fewer clean up steps; reduced acid use and recycle; low cost, industrial scale production of glucosamine and salts |
| 07/07/2005 | US20050148545 Better tasting dietary supplements; combined with such as citric acid |
| 07/07/2005 | US20050148543 Stable 9,10-dehydroepothilone and carrier concentrate |
| 07/07/2005 | US20050148541 Treatment and prevention of HIV and other viral infections |
| 07/07/2005 | US20050148539 Fused pentacyclic polyethers |
| 07/07/2005 | US20050148537 Immunostimulatory nucleic acid molecules |
| 07/07/2005 | US20050148534 Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
| 07/07/2005 | US20050148531 Antisense agents; blocking agents (biotin); high throughput screening |
| 07/07/2005 | US20050148527 Catalytic nucleic acids; ribozymes; translation inhibition; gene expression inhibition; for treating cardiovascular disease; for neovascularization induction in heart tissue |
| 07/07/2005 | US20050148526 Methods of obtaining isoform specific expression in mammalian cells |
| 07/07/2005 | US20050148524 Treating multiple myeloma via administering thalidomide and topoisomerase inhibitor such as irinotecan; side effect reduction |